Novavax, Inc. (NVAX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.25: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality. (Note: Risk dimension 2.1/10 and A.R:R 2.2:1 are different metrics that happen to read the same number here.)
Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19 vaccine (Nuvaxovid) is now fully commercialized by Sanofi under a 2024 collaboration agreement; Novavax earns milestones, royalties, and supply revenue.... Read more
Sell if holding. Engine safety override at $9.25: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality. (Note: Risk dimension 2.1/10 and A.R:R 2.2:1 are different metrics that happen to read the same number here.) Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Novavax, Inc.
Latest news
- Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb — benzinga May 11, 2026 positive
- What's Going On With Novavax Stock On Friday? — benzinga May 8, 2026 neutral
- Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- TD Cowen Maintains Hold on Novavax, Raises Price Target to $9 — benzinga May 6, 2026 neutral
- Why Novavax Stock Is Trading Higher On Wednesday? — benzinga May 6, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartySanofi (COVID-19 vaccine commercialization)10-K Item 1: 'In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™)'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Volatile — 7.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -14.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.25: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality. (Note: Risk dimension 2.1/10 and A.R:R 2.2:1 are different metrics that happen to read the same number here.) Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $8.60. Score 5.2/10, moderate confidence.
Take-profit target: $12.28 (+32.8% upside). Prior stop was $8.60. Stop-loss: $8.60.
Concentration risk — Counterparty: Sanofi (COVID-19 vaccine commercialization); Quality below floor (2.8 < 4.0).
Novavax, Inc. trades at a P/E of N/A (forward -16.4). TrendMatrix value score: 7.6/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19...
Novavax develops vaccines using its recombinant nanoparticle technology and proprietary Matrix-M adjuvant. Its COVID-19 vaccine (Nuvaxovid) is now fully commercialized by Sanofi under a 2024 collaboration agreement; Novavax earns milestones, royalties, and supply revenue. Matrix-M is also licensed to Serum Institute of India (R21 malaria vaccine), Takeda (Japan), and Pfizer (January 2026 agreement).